New antimicrobics for the treatment of infections caused by gram-negative bacilli.
D000667:Ampicillin / Q000627:therapeutic use; D000900:Anti-Bacterial Agents / Q000009:adverse effects / Q000627:therapeutic use*; D002509:Cephaloridine / Q000627:therapeutic use; D002512:Cephalothin / Q000627:therapeutic use; D003091:Colistin / Q000627:therapeutic use; D005839:Gentamicins / Q000627:therapeutic use; D006801:Humans; D007239:Infections / Q000188:drug therapy*; D008690:Methacycline / Q000627:therapeutic use; D009268:Nalidixic Acid / Q000627:therapeutic use
D000900:Anti-Bacterial Agents; D005839:Gentamicins; D009268:Nalidixic Acid; D000667:Ampicillin; D008690:Methacycline; D002509:Cephaloridine; D002512:Cephalothin; D003091:Colistin